Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | RPS6KA6 | Q9UK32 | 9/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | MARK3 | P27448 | 3/20 | 0.39 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CCND1 | P24385 | 2/20 | 0.39 |
| ▸ | CCND2 | P30279 | 2/20 | 0.39 |
| ▸ | CCND3 | P30281 | 2/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616799 | 0.83 | CDC7 (0.50) | JAK3AURKAAURKB | |
| SCHEMBL13616150 | 0.83 | ULK1 (0.46) | PLK1 | |
| SCHEMBL13616167 | 0.77 | CDK2 (0.57) | PLK1CCNE1CDK2 | |
| SCHEMBL2396085 | 0.77 | PLK1 (0.51) | BRD4PLK1MARK3MARK4MAPK7 | |
| SCHEMBL13616093 | 0.76 | RPS6KA6 (0.59) | RPS6KA6CDK4CCND1CCND2CCND3 | |
| SCHEMBL11976974 | 0.74 | RPS6KA6 (0.59) | JAK1JAK3RPS6KA6PLK1MARK3 | |
| SCHEMBL13616293 | 0.74 | CDK4 (0.60) | JAK1JAK3RPS6KA6PLK1MARK3 | |
| SCHEMBL13616297 | 0.74 | SYK (0.52) | JAK1JAK3RPS6KA6BRD4MARK3 | |
| SCHEMBL11977084 | 0.73 | CDK4 (0.49) | JAK1JAK3MARK3MARK4CDK4 | |
| SCHEMBL13616520 | 0.70 | CDK4 (0.55) | JAK1JAK3RPS6KA6BRD4MARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | JAK1 554/4885JAK3 716/4885RPS6KA6 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.